Optogenetics for Retinitis Pigmentosa

ReMedys has decided to accompany, on the path towards the clinic, a highly innovative project; optogenetics for the treatment of Retinitis Pigmentosa, RP, a group of severe eye disorders that cause progressive vision loss (https://ghr.nlm.nih.gov/condition/retinitis-pigmentosa & http://journals.plos.org/plosbiology/article?id=10.1371%2Fjournal.pbio.1002143).

ReMedys will be working to secure all the R&D support for bringing, this potential therapeutic solution, closer to RP patients.

A potential clinical entry is planned for 2019.

ReMedys Foundation to initiate a project in Gene Therapy for Amyotrophic Lateral Sclerosis

ReMedys Foundation has decided to accompany, on the path towards the clinic, a gene therapy project for the treatment of ALS caused by a mutation in the SOD1 gene (http://www.alsa.org/research/about-als-research/sod1.html, & http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338957)

This project shall be based on the R&D framework in ALS, that ReMedys established one year ago starting with a project from the Weizmann Institute of Science, to clinically reposition Enoxacin. Of note that, in February 2015, the European Medicines Agency granted ReMedys with an Orphan Medicinal Product Designation for the use of Enoxacin in ALS.

The Enoxacin project is planned to enter early clinical tests within 2017.

The SOD1 gene therapy project is planned to enter the clinic by the end of 2018.

ReMedys published an article in PLOS Neglected Tropical Diseases. The ReMedys model in action.

ReMedys has published, together with highly cited scientists around the globe, an article in PLOS Neglected Tropical Diseases. The article is a review of Opisthorchiasis, that is a highly overlooked danger affecting millions of people. The article is a launching milestone for a world wide consortium aiming to fight this neglected disease. ReMedys has acted to bring together resources and know how for increased effectiveness in the fight against the nematode causing Opisthorchiasis.

For more information please see at http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0003563

European Medicines Agency to grant ReMedys with an Orphan Medicinal Product Designation

The Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency, that is responsible for reviewing applications from people or companies seeking 'orphan-medicinal-product designation', issued on the12 of February 2015 a positive opinion on the ReMedys application for orphan drug designation for a generic drug that ReMedys is repositoning as a therapeutic option for the Amyotrophic Lateral Sclerosis.

Popular Pages